Calliditas Therapeutics Launches an Online Patient Platform
Calliditas Therapeutics AB (CALT) has launched IgAN Connect, a new online platform aimed at supporting individuals with IgA nephropathy, a serious autoimmune disease.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Calliditas Therapeutics AB (CALT) has launched IgAN Connect, a new online platform aimed at supporting individuals with IgA nephropathy, a serious autoimmune disease. This launch coincides with the inaugural IgAN Awareness Day. The platform offers resources for newly diagnosed patients and long-term sufferers, facilitating community connection and education. Andrew Udell, Calliditas' North America President, emphasized the platform's role in alleviating the challenges faced by patients. The platform is intended solely for educational purposes and does not provide medical advice.
Positive
- Launch of IgAN Connect provides valuable resources for individuals diagnosed with IgA nephropathy.
- Facilitates community support and education, potentially improving patient engagement.
Negative
- None.
Details
News Market Reaction – CALT
The recorded move for CALT in the trading session of this news was +2.40%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
This launch coincides with the inaugural IgAN Awareness Day
STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease.
IgANConnect.com provides individuals who have just been diagnosed with IgA nephropathy, those who have been living with the disease for many years, and caregivers the tools to help understand and manage IgA nephropathy.
The complimentary IgAN Connect Facebook page provides an environment where individuals living with the disease are encouraged to explore educational and motivational resources alongside other members of the community.
“As a rare and chronic autoimmune disease with more than
Bonnie Schneider, Director and Co-Founder of the IgA Nephropathy Foundation of America commented, “IgA nephropathy is a complicated disease that can leave individuals with many unanswered questions. With the launch of IgAN Connect, I am grateful that individuals will have even more resources to embark on this journey.”
IgANConnect.com is intended for educational purposes only. It is not intended to provide medical advice. Every individual’s medical situation is different, so any questions should be directed to a healthcare professional.
For further information, please contact:
Marie Galay, IR Manager, Calliditas
Tel.: +44 79 55 12 98 45, email: marie.galay@calliditas.com
Sky Striar, Media Contact, LifeSci Communications
Tel: +1.617.797.6672, email: sstriar@lifescicomms.com
About Primary Immunoglobulin A Nephropathy
Primary immunoglobulin A nephropathy (IgA nephropathy or IgAN or Berger’s Disease) is a rare, progressive, chronic autoimmune disease that attacks the kidneys and occurs when galactose-deficient IgA1 are recognized by autoantibodies, creating IgA1 immune complexes that become deposited in the glomerular mesangium of the kidney.1,2 This deposition in the kidney can lead to progressive kidney damage and potentially a clinical course resulting in end-stage renal disease. IgAN most often develops between late teens and late 30s.2,3
About Calliditas
Calliditas Therapeutics is a commercial stage biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
Calliditas’ common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).
- Barratt, J., & Feehally, J. (2005). IgA nephropathy. J Am Soc Nephrol, 16(7), 2088-2097. https://doi.org/10.1681/ASN.2005020134
- Barratt, J., Rovin, B. H., Cattran, D., et al. (2020). Why Target the Gut to Treat IgA Nephropathy? Kidney Int Rep, 5(10), 1620 1624. https://doi.org/10.1016/j.ekir.2020.08.009
- Jarrick, S., Lundberg, S., Welander, A., et al. (2019). Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study. J Am Soc Nephrol, 30(5), 866-876. https://doi.org/10.1681/ASN.2018101017
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.